Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Completed 4Suspended 1Active not recruiting 1

Sponsor Class

INDUSTRY 42OTHER 32NETWORK 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1

Interventions

Specimen Handling 188Magnetic Resonance Spectroscopy 143Biopsy 116Nivolumab 39X-Rays 29Immunoglobulin G 29Disulfides 29Radiation 28Carboplatin 27atezolizumab 25Taxes 25Paclitaxel 25pembrolizumab 23Radiotherapy 23Ipilimumab 23CTLA-4 Antigen 23olaparib 22Cyclophosphamide 22Cisplatin 21Platinum 20Gemcitabine 20Doxorubicin 20Bevacizumab 201,2-diaminocyclohexaneplatinum II citrate 20Phantoms, Imaging 19Vincristine 17trametinib 16cabozantinib 15Rituximab 15ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × NIH × 130-nm albumin-bound paclitaxel × Clear all
NCT04310007 2026-05-29

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
117 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡